Tucatinib Recommended Dosage and Daily Dosage
Tucatinib (Tucatinib) is an oral small molecule HER2 tyrosine kinase inhibitor, mainly used to treat HER2-positive breast cancer, especially for advanced or metastatic patients who have received multiple lines of treatment. It is often combined with trastuzumab and capecitabine to increase efficacy. Because the drug is highly selective for HER2, it can reduce the inhibition of EGFR during treatment, thereby reducing the incidence of side effects such as rash and diarrhea.
In the recommended combination treatment regimen, the standard usage of tucatinib is oral administration, twice daily. The recommended dose is 300mg each time, usually once in the morning and evening, with food or on an empty stomach. It should be noted that tucatinib should be swallowed whole and should not be broken or chewed to ensure normal absorption of the drug in the body. In terms of co-medication, the dosages of trastuzumab and capecitabine need to be adjusted according to the instructions and doctor's recommendations to minimize toxicity and improve therapeutic effect.

During the treatment process, patients should follow the doctor’s instructions to conduct regular liver function monitoring and imaging examinations to evaluate treatment response and side effects. In particular, tucatinib has a certain impact on liver function, so ALT, AST and bilirubin levels need to be measured regularly before and during medication. If adverse reactions of Grade 3 or above occur, such as severe diarrhea, liver damage, or hand-foot syndrome, your doctor may recommend suspending the medication or adjusting the dose.
In summary, tucatinib, as part of HER2 targeted therapy, brings new hope to patients with advanced breast cancer. Its standard dosage is 300mg twice daily, which is an effective regimen confirmed by clinical trials. However, you should pay close attention to your body's reaction during medication, follow your doctor's instructions, and avoid adjusting the dosage or interrupting treatment on your own.
Reference materials:https://www.drugs.com/
[ 免责声明 ] 本页面内容来自公开渠道(如FDA官网、Drugs官网、原研药厂官网等),仅供持有医疗专业资质的人员用于医学药学研究参考,不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市,不适用于中国境内销售和使用。如需治疗,请咨询正规医疗机构。本站不提供药品销售或代购服务。
.jpeg)